Slingshot Insights

Catalyst

Slingshot members are tracking this event:

FDA decision on Drisapersen approval in DMD: PDUFA 12/27/15

Source Link:: http://investors.bmrn.com/releasedetail.cfm?releaseid=919809

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

SRPT

100%

PTCT

33%

BMRN

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details FDA has notified the Company that they had not yet completed their review process and would be unable to take an action by the PDUFA action date for Kyndrisa (drisapersen) of December 27, 2015, and anticipate taking action in early January 2016.

http://investors.bmr...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jan 14, 2016

Occurred Source:

http://investors.bmrn.com/releasedetail.cfm?ReleaseID=950309

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Dmd, Drisapersen, Duchenne Muscular Dystrophy, Eteplirsen, Kyndrisa